睿知中国医院研究地图
候选清单

上海上海交通大学医学院

上海交通大学医学院附属瑞金医院

Ruijin Hospital

在本站收录的 53 种疾病中,这家医院列在其中 24 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

上海交通大学医学院附属瑞金医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma22 篇牵头论文牵头 1 项开放试验
  2. 肝细胞癌Hepatocellular carcinoma35 篇牵头论文牵头 3 项开放试验
  3. 胃癌Stomach cancer96 篇牵头论文牵头 13 项开放试验
  4. 骨肉瘤Osteosarcoma13 篇牵头论文牵头 1 项开放试验
  5. 胃肠道间质瘤Gastrointestinal stromal tumour2 篇牵头论文
  6. 神经母细胞瘤Neuroblastoma2 篇牵头论文
  7. 尤文肉瘤Ewing sarcoma0 篇牵头论文
  8. 多发性骨髓瘤Multiple myeloma22 篇牵头论文
  9. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia11 篇牵头论文牵头 4 项开放试验
  10. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis2 篇牵头论文
  11. β 地中海贫血Beta thalassaemia0 篇牵头论文
  12. 血友病 AHaemophilia A5 篇牵头论文
  13. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura0 篇牵头论文
  14. 烟雾病Moyamoya disease2 篇牵头论文
  15. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis1 篇牵头论文
  16. 特发性肺纤维化Idiopathic pulmonary fibrosis0 篇牵头论文
  17. 肺淋巴管平滑肌瘤病Lymphangioleiomyomatosis2 篇牵头论文
  18. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis2 篇牵头论文
  19. 脊髓性肌萎缩症Spinal muscular atrophy0 篇牵头论文
  20. 法布雷病Fabry disease3 篇牵头论文
  21. Alport 综合征Alport syndrome1 篇牵头论文
  22. IgA 肾病IgA nephropathy4 篇牵头论文牵头 2 项开放试验
  23. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
  24. 家族性腺瘤性息肉病Familial adenomatous polyposis2 篇牵头论文

未列出的收录疾病:鼻咽癌、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、再生障碍性贫血、非典型溶血性尿毒症综合征、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、肝豆状核变性、胆道闭锁、大动脉炎、肝包虫病、庞贝病、杜氏肌营养不良、白塞病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 22 篇,占 0.8%。

牵头论文
22
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 3320232024: 5520242025: 992025

上海有 18 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
    分期
    不分期
    开始
    2024-06
    登记号
    NCT06596954

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  2. 正在招募
    Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2023-01
    登记号
    NCT05978193

    年龄 18 岁 至 未注明(登记的条件)

    牵头:上海市胸科医院;另有 1 家列出的医院为研究中心上海

  3. 正在招募
    Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
    分期
    III期
    开始
    2019-09
    登记号
    NCT04135664

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海市胸科医院;另有 5 家列出的医院为研究中心上海、南昌、天津

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题新辅助与综合治疗放疗免疫治疗
论文中的科室放疗科肿瘤内科
牵头的论文22
  1. The Clinical Value of hsa_circ_0000419 in Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma.2026Biochemical genetics
  2. Neoadjuvant camrelizumab combined with chemoradiotherapy and watch-and-wait strategy versus neoadjuvant chemoradiotherapy followed by surgery in locally advanced oesophageal squamous cell carcinoma: study protocol of a randomised controlled2025BMJ open免费全文
  3. Sparing lymphocytes during preoperative adjuvant radiotherapy for oesophageal squamous cell carcinoma (SPARE): protocol for an open-label, randomised controlled trial.2025BMJ open免费全文
  4. CT radiomics to predict pathologic complete response after neoadjuvant immunotherapy plus chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.2025European radiology
  5. Residual pattern of primary tumor and lymph node in ESCC treated with nCRT with or without pembrolizumab: an analysis from a prospective cohort.2025Frontiers in immunology免费全文
  6. TROAP promotes esophageal squamous cell carcinoma progression via the PI3K/AKT pathway.2025Journal of cancer research and clinical oncology免费全文
  7. Radiomics applications in the modern management of esophageal squamous cell carcinoma.2025Medical oncology (Northwood, London, England)
  8. Characterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell carcinoma: an analysis of a prospective cohort.2025Radiation oncology (London, England)免费全文
  9. Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2).2025Signal transduction and targeted therapy免费全文
  10. Retrospective Analysis of CT-based Habitat Analysis for Predicting pCR and Survival of ESCC Treated by Neoadjuvant Chemoradiotherapy and Esophagectomy.2025Technology in cancer research & treatment免费全文
  11. The addition of pembrolizumab to neoadjuvant chemoradiotherapy did not increase the risk of developing postoperative anastomotic leakage for ESCC: an analysis from a prospective cohort.2024BMC cancer免费全文
  12. Integrative genomics unveils basement membrane-related diagnostic markers and therapeutic targets in esophageal squamous cell carcinoma.2024Biology direct免费全文
  13. A novel computational model ITHCS for enhanced prognostic risk stratification in ESCC by correcting for intratumor heterogeneity.2024Briefings in bioinformatics免费全文
  14. Real-world evaluation of multimodal treatment practice in older oesophageal cancer patients.2024European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  15. A machine learning approach using 18F-FDG PET and enhanced CT scan-based radiomics combined with clinical model to predict pathological complete response in ESCC patients after neoadjuvant chemoradiotherapy and anti-PD-1 inhibitors.2024Frontiers in immunology免费全文
  16. Robotic Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer: A Meta-analysis.2023Annals of surgery
  17. High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy.2023Journal for immunotherapy of cancer免费全文
  18. Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort.2023Thoracic cancer免费全文
  19. Comment on "Toxic epidermal necrolysis during camrelizumab treatment for oesophageal squamous cell carcinoma".2022Contact dermatitis
  20. Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).2022Future oncology (London, England)
  21. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1).2021European journal of cancer (Oxford, England : 1990)
  22. Beclin-1 is a Promising Prognostic Biomarker in a Specific Esophageal Squamous Cell Carcinoma Population.2021Pathology oncology research : POR免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
  1. Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma正在招募NCT06596954牵头方不分期2024-06 启动
  2. Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma状态不明NCT06122493牵头方II期2022-11 启动
  3. Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma已完成NCT04435197牵头方II期2020-08 启动
  4. Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus已完成NCT03792347牵头方(推断)I期2019-01 启动
  5. Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma正在招募NCT05978193研究中心II期2023-01 启动
  6. Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma正在招募NCT04135664研究中心III期2019-09 启动
  7. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma已终止NCT05461794研究中心II期2022-10 启动
  8. Robot-assisted Esophagectomy Versus Conventional Thoracoscopic Esophagectomy状态不明NCT03094351研究中心III期2017-07 启动
  9. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study已完成NCT03933449研究中心III期2016-12 启动
  10. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)已完成NCT02649361研究中心II期2016-01 启动
  11. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma状态不明NCT02611700研究中心III期2015-11 启动
PubMed 以外找到的论文(未计入)21
  1. Association of Skeletal Muscle and Adiposity Measured by Computed Tomography with Toxicity and pCR in Esophageal Squamous Cell Carcinoma Receiving Standardized Neoadjuvant Chemoradiotherapy2025International Journal of Radiation Oncology*Biology*Physics论文
  2. The Predictive Value of Pretreatment Peripheral T-Lymphocyte Subsets for Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma Patients Undergoing Neoadjuvant Chemoradiotherapy: A Prospective Cohort Analysis2025International Journal of Radiation Oncology*Biology*Physics论文
  3. Abstract CT213: Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C2024Cancer Research会议摘要
  4. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C.2024Journal of Clinical Oncology会议摘要
  5. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C.2024Journal of Clinical Oncology会议摘要
  6. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from multi-cohort, multi-center phase II trial ALTER-G-001-cohort A.2024Journal of Clinical Oncology会议摘要
  7. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncology会议摘要
  8. First Exploration of the Characterization and Dosimetric Predictors for Absolute Lymphocyte Count Changes during nCRT with or without Pembrolizumab for Esophageal Squamous Cell Carcinoma: An Analysis of a Prospective Cohort2024International Journal of Radiation Oncology*Biology*Physics论文
  9. 103P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A2023Annals of Oncology论文
  10. 150P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C2023Annals of Oncology论文
  11. 1628P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)2023Annals of Oncology论文
  12. A propensity score–matched analysis to evaluate the benefit of adjuvant therapy on disease progression of esophageal squamous cell carcinoma after R0 esophagectomy.2023Journal of Clinical Oncology会议摘要
  13. Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway2023Figshare数据集
  14. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001).2023Journal of Clinical Oncology会议摘要
  15. P-104 Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)2023Annals of Oncology会议摘要
  16. Prediction of Response to Neoadjuvant Chemoradiotherapy Combined with Pembrolizumab in Esophageal Squamous Cell Carcinoma with CT/FDG PET Radiomic Signatures Based on Machine Learning Classification2023International Journal of Radiation Oncology*Biology*Physics论文
  17. Sarcopenia as a Predictor of Neoadjuvant Therapy-Related Toxicity in Esophageal Squamous Cell Carcinoma Patients2023International Journal of Radiation Oncology*Biology*Physics论文
  18. Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: A multicenter, multicohort clinical trial (ALTER-G-001).2022Journal of Clinical Oncology会议摘要
  19. Exosomes-derived miR-154-5p attenuates esophageal squamous cell carcinoma progression and angiogenesis by targeting kinesin family member 142022Figshare数据集
  20. Postoperative Radiotherapy Involving Tumor Bed with or without Elective Nodal Irradiation in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center, Prospective Randomized Phase II Trial2022International Journal of Radiation Oncology*Biology*Physics论文
  21. Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma2021Annals of Surgery论文

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 35 篇,占 0.2%。

牵头论文
35
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
3
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 6620222023: 5520232024: 9920242025: 772025

上海有 15 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
    分期
    II期
    开始
    2025-11
    登记号
    NCT07331883

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院;另有 2 家列出的医院为研究中心上海、长春

  2. 正在招募
    The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
    分期
    未注明
    开始
    2024-12
    登记号
    NCT06746194

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  3. 正在招募
    Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
    分期
    未注明
    开始
    2023-03
    登记号
    NCT05870969

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  4. 正在招募
    JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
    分期
    II期
    开始
    2025-05
    登记号
    NCT06954467

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、合肥、哈尔滨、沈阳、郑州、长沙

  5. 即将招募
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    分期
    未注明
    开始
    2025-08
    登记号
    NCT07100236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、合肥、广州、杭州、温州、福州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现乙肝与肝硬化
论文中的科室普外/肝胆胰外科影像/核医学科病理/检验科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文35
  1. RIPPLY1 suppresses cancer cell stemness via targeting TBX19 in CTNNB1 -mutated hepatocellular carcinoma.2026Hepatology (Baltimore, Md.)
  2. Radiomics with Machine Learning Improves the Prediction of Microscopic Peritumoral Small Cancer Foci and Early Recurrence in Hepatocellular Carcinoma.2025Academic radiology
  3. Suppression of pseudogene MT2P1 transcription induced by E2F7 inhibits hepatocellular carcinoma cell proliferation and facilitates apoptosis via preserving its parental gene.2025Cancer biology & therapy免费全文
  4. Ascending E2F7a/b ratio facilitates KLF13 transcription in hepatocellular carcinoma and correlates with the abundance of binuclear hepatocytes (ABH) modulation for short-term recurrence.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology免费全文
  5. Single-Gene Mutations in Hepatocellular Carcinoma: Applications and Challenges in Precision Medicine.2025International journal of medical sciences免费全文
  6. Preoperative Multifrequency MR Elastography for Stratifying Wnt/β-Catenin Pathway and Microvascular Invasion Phenotypes in Hepatocellular Carcinoma.2025Journal of magnetic resonance imaging : JMRI免费全文
  7. Paracancerous binuclear hepatocytes assessed by computer program is a novel biomarker for short term recurrence of hepatocellular carcinoma after surgery.2025Scientific reports免费全文
  8. A Nanoplatform of Reversing Tumor Immunosuppressive Microenvironment Based on the NIR-II Gold Hollow Nanorod for the Treatment of Hepatocellular Carcinoma.2025Small (Weinheim an der Bergstrasse, Germany)
  9. Interim analysis of the PARADISE study: Benefits of add-on peginterferon-α in NA-treated patients with CHB.2024Antiviral researchRCT
  10. Astragaloside IV inhibits cell viability and glycolysis of hepatocellular carcinoma by regulating KAT2A-mediated succinylation of PGAM1.2024BMC cancer免费全文
  11. The prognostic and antitumor roles of key genes of ferroptosis in liver hepatocellular cancer and stomach adenocarcinoma.2024Cancer biomarkers : section A of Disease markers免费全文
  12. FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study.2024Frontiers in immunology免费全文
  13. METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation.2024Journal of hematology & oncology免费全文
  14. Three-Dimensional Multifrequency MR Elastography for Microvascular Invasion and Prognosis Assessment in Hepatocellular Carcinoma.2024Journal of magnetic resonance imaging : JMRI
  15. Risk predictive model for the development of hepatocellular carcinoma before initiating long-term antiviral therapy in patients with chronic hepatitis B virus infection.2024Journal of medical virology
  16. Alternative splicing-related long noncoding RNA ANRIL facilitates hepatocellular carcinoma by targeting the miR-199a-5p/SRSF1 axis and impacting Anillin.2024Molecular carcinogenesis
  17. Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study.2024PLoS medicine免费全文
  18. Silencing of KNTC1 inhibits hepatocellular carcinoma cells progression via suppressing PI3K/Akt pathway.2023Cellular signalling
  19. Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma.2023Clinical and experimental medicine免费全文
  20. Attenuation of binuclear hepatocytes in the paracancerous liver tissue is associated with short-term recurrence of hepatocellular carcinoma post-radical surgery.2023FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  21. Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma.2023Journal of advanced research免费全文
  22. Editorial for "LI-RADS Category on MRI Is Associated With Recurrence of Intrahepatic Cholangiocarcinoma After Surgery: A Multicenter Study".2023Journal of magnetic resonance imaging : JMRI
  23. Pseudogene UBE2MP1 derived transcript enhances in vitro cell proliferation and apoptosis resistance of hepatocellular carcinoma cells through miR-145-5p/RGS3 axis.2022Aging免费全文
  24. Circular RNA circ SET domain containing 2 (circSETD2) inhibits hepatocellular carcinoma cell proliferation and invasion in vivo and in vitro.2022Bioengineered免费全文
  25. Overexpressed Histocompatibility Minor 13 was Associated with Liver Hepatocellular Carcinoma Progression and Prognosis.2022Genetics research免费全文
  26. PITX2C increases the stemness features of hepatocellular carcinoma cells by up-regulating key developmental factors in liver progenitor.2022Journal of experimental & clinical cancer research : CR免费全文
  27. E2F7 enhances hepatocellular carcinoma growth by preserving the SP1/SOX4/Anillin axis via repressing miRNA-383-5p transcription.2022Molecular carcinogenesis免费全文
  28. Pseudogene SNRPFP1 derived long non-coding RNA facilitates hepatocellular carcinoma progress in vitro by sponging tumor-suppressive miR-126-5p.2022Scientific reports免费全文
  29. Identification of prognostic long non-coding RNA signature with potential drugs in hepatocellular carcinoma.2021Aging免费全文
  30. Immunological effect of irreversible electroporation on hepatocellular carcinoma.2021BMC cancer免费全文
  31. Identification of Key Biological Processes, Pathways, Networks, and Genes with Potential Prognostic Values in Hepatocellular Carcinoma Using a Bioinformatics Approach.2021Cancer biotherapy & radiopharmaceuticals
  32. PHF19 activates hedgehog signaling and promotes tumorigenesis in hepatocellular carcinoma.2021Experimental cell research
  33. ACTN1 supports tumor growth by inhibiting Hippo signaling in hepatocellular carcinoma.2021Journal of experimental & clinical cancer research : CR免费全文
  34. Feasibility of automatic detection of small hepatocellular carcinoma (≤2 cm) in cirrhotic liver based on pattern matching and deep learning.2021Physics in medicine and biology
  35. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.2021Theranostics免费全文
中文论文(未计入)3
  1. [Value of albumin RNAscope in situ hybridization in diagnosis and differential diagnosis of hepatocellular carcinoma].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Standardized screening and early imaging diagnosis strategies for hepatocellular carcinoma].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  3. [Risk assessment and management of hepatocellular carcinoma occurrence in patients with chronic hepatitis B in the era of antiviral therapy].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
  1. Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)正在招募NCT07331883牵头方II期2025-11 启动
  2. The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy正在招募NCT06746194牵头方2024-12 启动
  3. Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)正在招募NCT05870969牵头方2023-03 启动
  4. Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis状态不明NCT04160897牵头方(推断)2019-10 启动
  5. 29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness即将招募NCT07100236研究中心2025-08 启动
  6. JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma正在招募NCT06954467研究中心II期2025-05 启动
  7. Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma状态不明NCT05389527研究中心II期2022-09 启动
  8. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev进行中,不再招募NCT04649489研究中心III期2021-04 启动
  9. Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients状态不明NCT05343832研究中心2021-11 启动
  10. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer已终止NCT04520906研究中心不分期2020-12 启动
  11. A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients状态不明NCT05671315研究中心不分期2019-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 96 篇,占 1.0%。

牵头论文
96
2021–2025 年
牵头试验
31
任何状态,ClinicalTrials.gov
牵头的开放试验
13
正在或即将招募
作为研究中心的开放试验
10
由其他机构牵头
每年牵头的论文数
2021: 141420212022: 242420222023: 171720232024: 202020242025: 21212025

上海有 18 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 23

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
    分期
    II期
    开始
    2026-04
    登记号
    NCT07556640

    年龄 18 岁 至 未注明(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  2. 正在招募
    Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
    分期
    II期
    开始
    2025-02
    登记号
    NCT06519591

    年龄 18 岁 至 未注明(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  3. 正在招募
    IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
    分期
    I/II期
    开始
    2025-06
    登记号
    NCT07025889

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  4. 正在招募
    Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
    分期
    II期
    开始
    2025-06
    登记号
    NCT07026149

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  5. 正在招募
    Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
    分期
    III期
    开始
    2025-12
    登记号
    NCT07366528

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院;另有 3 家列出的医院为研究中心上海

  6. 正在招募
    Predicting Efficacy of Preoperative Immunotherapy in Advanced Gastric Cancer
    分期
    未注明
    开始
    2025-06
    登记号
    NCT07824479

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  7. 正在招募
    Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
    分期
    II期
    开始
    2025-02
    登记号
    NCT07867392

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  8. 正在招募
    The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
    分期
    未注明
    开始
    2024-06
    登记号
    NCT06597526

    年龄 18 岁 至 未注明(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  9. 正在招募
    Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer
    分期
    不分期
    开始
    2020-09
    登记号
    NCT05140746

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  10. 即将招募
    Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging
    分期
    未注明
    开始
    2026-04
    登记号
    NCT07554742

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  11. 即将招募
    GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
    分期
    I期
    开始
    2026-11
    登记号
    NCT07923396

    年龄 18 岁 至 未注明(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  12. 即将招募
    Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer
    分期
    II期
    开始
    2025-03
    登记号
    NCT06888037

    年龄 18 岁 至 未注明(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  13. 即将招募
    Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
    分期
    III期
    开始
    2021-09
    登记号
    NCT04384601

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  14. 正在招募
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    分期
    未注明
    开始
    2025-02
    登记号
    NCT06846996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春

  15. 正在招募
    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
    分期
    III期
    开始
    2025-05
    登记号
    NCT06901531

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、成都、杭州、武汉、石家庄、福州、郑州

  16. 正在招募
    Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer:MetBio-CRC
    分期
    未注明
    开始
    2025-06
    登记号
    NCT07068529

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

  17. 正在招募
    Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer:MetBio-GC
    分期
    未注明
    开始
    2025-06
    登记号
    NCT07076979

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

  18. 正在招募
    DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
    分期
    II/III期
    开始
    2024-02
    登记号
    NCT06221748

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、厦门、哈尔滨、徐州、成都、昆明、武汉、济南、郑州、长沙、青岛

  19. 正在招募
    Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study
    分期
    不分期
    开始
    2024-12
    登记号
    NCT06679244

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:复旦大学附属华山医院;另有 2 家列出的医院为研究中心上海

  20. 正在招募
    Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
    分期
    III期
    开始
    2023-04
    登记号
    NCT05918094

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 6 家列出的医院为研究中心上海、南昌、哈尔滨、广州、成都、武汉、郑州

  21. 正在招募
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    分期
    未注明
    开始
    2023-09
    登记号
    NCT06035250

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南宁、天津、广州、昆明、沈阳、福州、苏州、郑州、长沙、青岛

  22. 正在招募
    A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
    分期
    I期
    开始
    2022-06
    登记号
    NCT05365581

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、广州、杭州、武汉、郑州

  23. 即将招募
    Prospective Assessment of Alignment Between Multimodal Artificial Intelligence and Multidisciplinary Team Decisions in Gastrointestinal Oncology
    分期
    未注明
    开始
    2026-08
    登记号
    NCT07746830

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期化疗与综合治疗影像与人工智能
论文中的科室普外/肝胆胰外科肿瘤内科影像/核医学科病理/检验科
牵头的论文96
  1. Super-enhancer Activates Master Transcription Factor NR3C1 Expression and Promotes 5-FU Resistance in Gastric Cancer.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Lenvatinib Plus Paclitaxel as Second-Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. Machine Learning-Driven SERS Analysis Platform for Accurate and Rapid Diagnosis of Peritoneal Metastasis from Gastric Cancer.2025Annals of surgical oncology
  4. Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immuno2025BMC cancer免费全文
  5. Loss of DRD5P2 in hypoxia attenuates Rock2 degradation to promote EMT and gastric cancer metastasis.2025Biochimica et biophysica acta. Molecular basis of disease
  6. USP4-Mediated deubiquitination of A2AR suppresses autophagy-dependent ferroptosis in gastric cancer.2025Cellular and molecular life sciences : CMLS免费全文
  7. Deciphering of intra-tumoural heterogeneity and the interplay between metastasis-associated meta-program and myofibroblasts in gastric cancer.2025Clinical and translational medicine免费全文
  8. Prediction of tumor regression grade in far-advanced gastric cancer after preoperative immuno-chemotherapy using dual-energy CT-derived extracellular volume fraction.2025European radiology
  9. Clinical and body composition parameters as predictors of response to chemotherapy plus PD-1 inhibitor in gastric cancer.2025Frontiers in immunology免费全文
  10. Predictive value of label-free surface-enhanced Raman spectroscopy for locally advanced gastric cancer following neoadjuvant chemoimmunotherapy.2025Frontiers in immunology免费全文
  11. Gallstones, cholecystectomy, and cancer risk: an observational and Mendelian randomization study.2025Frontiers of medicine
  12. Asian consensus on normothermic intraperitoneal and systemic treatment for gastric cancer with peritoneal metastasis.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  13. Resveratrol targets mitochondrial USP36-SOD2 to induce autophagy-ferroptosis and inhibit gastric cancer progression.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  14. FLOT vs DOS neoadjuvant chemotherapy in locally advanced gastric cancer: propensity score analysis.2025International journal of clinical oncology
  15. SIGLEC11 promotes M2 macrophage polarization through AKT-mTOR signaling and facilitates the progression of gastric cancer.2025Journal for immunotherapy of cancer免费全文
  16. Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05).2025Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT免费全文
  17. Malignant gastric glomus tumor with heterochronous liver metastases: a case report and review of the literature.2025Journal of medical case reports免费全文
  18. Multi-Omics Analysis Reveals OBSCN as a Key Modulator of Tumor Microenvironment, Microbial Signatures and Clinical Outcomes in Gastric Cancer.2025MicrobiologyOpen免费全文
  19. Raman spectroscopy analysis combined with computed tomography imaging to identify microsatellite instability in gastric cancers.2025Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  20. Overlap Versus π-Shaped Esophagojejunostomy After Laparoscopic Total Gastrectomy for Gastric Cancer: A Comparative Study.2025Surgical laparoscopy, endoscopy & percutaneous techniques
  21. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in gastric adenosquamous carcinoma.2025Virchows Archiv : an international journal of pathology免费全文
  22. The efficacy of neoadjuvant chemotherapy is different for type 4 and large type 3 gastric cancer.2024American journal of surgery
  23. Improving diagnosis and outcome prediction of gastric cancer via multimodal learning using whole slide pathological images and gene expression.2024Artificial intelligence in medicine
  24. The prognostic and antitumor roles of key genes of ferroptosis in liver hepatocellular cancer and stomach adenocarcinoma.2024Cancer biomarkers : section A of Disease markers免费全文
  25. PHF10 inhibits gastric epithelium differentiation and induces gastric cancer carcinogenesis.2024Cancer gene therapy免费全文
  26. Drug-induced senescence by aurora kinase inhibitors attenuates innate immune response of macrophages on gastric cancer organoids.2024Cancer letters免费全文
  27. The effect of self-designed metabolic equivalent exercises on cancer-related fatigue in patients with gastric cancer: A randomized controlled trial.2024Cancer medicineRCT免费全文
  28. SLC7A9 suppression increases chemosensitivity by inducing ferroptosis via the inhibition of cystine transport in gastric cancer.2024EBioMedicine免费全文
  29. In-hospital outcomes of older patients with gastric cancer and their risk factors: large comprehensive institution-based study.2024European geriatric medicine
  30. Perioperative systemic and prophylactic intraperitoneal chemotherapy for type 4/large type 3 gastric cancer: DRAGON-10.2024Future oncology (London, England)免费全文
  31. Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  32. Comprehensive multi-omics analysis and experimental verification reveal PFDN5 is a novel prognostic and therapeutic biomarker for gastric cancer.2024Genomics
  33. Cytotoxic effects of NIR responsive chitosan-polymersome layer coated melatonin-upconversion nanoparticles on HGC27 and AGS gastric cancer cells: Role of the ROS/PI3K/Akt/mTOR signaling pathway.2024International journal of biological macromolecules
  34. Blocking EGR1/TGF-β1 and CD44s/STAT3 Crosstalk Inhibits Peritoneal Metastasis of Gastric Cancer.2024International journal of biological sciences免费全文
  35. GC-CDSS: Personalized gastric cancer treatment recommendations system based on knowledge graph.2024International journal of medical informatics
  36. Value of 68Ga-FAPI-04 and 18F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.2024Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  37. Paired organoids from primary gastric cancer and lymphatic metastasis are useful for personalized medicine.2024Journal of translational medicine免费全文
  38. Development of Aptamer-DNAzyme based metal-nucleic acid frameworks for gastric cancer therapy.2024Nature communications免费全文
  39. Tumor-mesothelium HOXA11-PDGF BB/TGF β1-miR-181a-5p-Egr1 feedforward amplifier circuity propels mesothelial fibrosis and peritoneal metastasis of gastric cancer.2024Oncogene免费全文
  40. VPS35 promotes gastric cancer progression through integrin/FAK/SRC signalling-mediated IL-6/STAT3 pathway activation in a YAP-dependent manner.2024Oncogene免费全文
  41. Latest guideline of endoscopic submucosal dissection of early gastric cancer may not be suitable for Chinese patients: retrospective study findings from two centers.2024Surgical endoscopy免费全文
  42. CT-Based Radiomic Score: A Risk Stratifier in Far-Advanced Gastric Cancer Patients.2023Academic radiologyRCT
  43. Efficacy and prognostic value of delta radiomics on dual-energy computed tomography for gastric cancer with neoadjuvant chemotherapy: a preliminary study.2023Acta radiologica (Stockholm, Sweden : 1987)RCT
  44. BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C-MYC/PLCG1/Perk Axis.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  45. Androgen receptor promotes cell stemness via interacting with co-factor YAP1 in gastric cancer.2023Biochemical pharmacology
  46. The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.2023Cancer medicine免费全文
  47. HNF4A-BAP31-VDAC1 axis synchronously regulates cell proliferation and ferroptosis in gastric cancer.2023Cell death & disease免费全文
  48. VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancer.2023EBioMedicine免费全文
  49. Utility of [68Ga]FAPI-04 and [18F]FDG dual-tracer PET/CT in the initial evaluation of gastric cancer.2023European radiology免费全文
  50. Sintilimab combined neoadjuvant intraperitoneal and systemic chemotherapy in gastric cancer with peritoneal metastasis.2023Future oncology (London, England)
  51. Exosomal hsa-let-7g-3p and hsa-miR-10395-3p derived from peritoneal lavage predict peritoneal metastasis and the efficacy of neoadjuvant intraperitoneal and systemic chemotherapy in patients with gastric cancer.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  52. Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling.2023International journal of biological sciences免费全文
  53. A combined radiomic model distinguishing GISTs from leiomyomas and schwannomas in the stomach based on endoscopic ultrasonography images.2023Journal of applied clinical medical physics免费全文
  54. Paracrine activin B-NF-κB signaling shapes an inflammatory tumor microenvironment in gastric cancer via fibroblast reprogramming.2023Journal of experimental & clinical cancer research : CR免费全文
  55. Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer.2023Matrix biology : journal of the International Society for Matrix Biology
  56. Intra-abdominal fat volume estimation by multi-detector rows computed tomography: relevance in surgical fellowship training program in Shanghai: a retrospective study.2023PeerJ免费全文
  57. Cancer-associated fibroblasts impair the cytotoxic function of NK cells in gastric cancer by inducing ferroptosis via iron regulation.2023Redox biology免费全文
  58. Euclidean distance-based Raman spectroscopy (EDRS) for the prognosis analysis of gastric cancer: A solution to tumor heterogeneity.2023Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  59. CPT1C promotes the potential of gastric cancer ovarian metastasis through up-regulating fatty acid oxidation.2022Acta biochimica et biophysica Sinica免费全文
  60. Long non-coding RNA NUT family member 2A-antisense RNA 1 sponges microRNA-613 to increase the resistance of gastric cancer cells to matrine through regulating oxidative stress and vascular endothelial growth factor A.2022Aging免费全文
  61. A Modified Billroth-II with Braun Anastomosis in Totally Laparoscopic Distal Gastrectomy: Initial Experience Compared with Roux-en-Y Anastomosis.2022Annals of surgical oncology
  62. Initial screening of gastric cancer using oral contrast-enhanced trans-abdominal ultrasonography in rural asymptomatic individuals.2022Cancer epidemiology
  63. LncRNA LENGA acts as a tumor suppressor in gastric cancer through BRD7/TP53 signaling.2022Cellular and molecular life sciences : CMLS免费全文
  64. CRISPR/Cas9-mediated knockout of SGLT1 inhibits proliferation and alters metabolism of gastric cancer cells.2022Cellular signalling
  65. Prognostic role of iodine values for gastric cancer after neoadjuvant chemotherapy: a strong independent prognostic factor.2022Diagnostic and interventional radiology (Ankara, Turkey)免费全文
  66. Endoscopic closure of a large gastric mucosal defect after endoscopic submucosal dissection using a novel endoscopic string-with-knotter suture device.2022Endoscopy
  67. Evaluation of dual-energy CT derived radiomics signatures in predicting outcomes in patients with advanced gastric cancer after neoadjuvant chemotherapy.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  68. CHRDL2 promotes cell proliferation by activating the YAP/TAZ signaling pathway in gastric cancer.2022Free radical biology & medicine
  69. Identification of prognostic gene expression signatures based on the tumor microenvironment characterization of gastric cancer.2022Frontiers in immunology免费全文
  70. Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies.2022Frontiers in immunology免费全文
  71. Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer.2022Future oncology (London, England)
  72. A phase II study of perioperative treatment in gastric cancer with No.16a2/b1 lymph node metastasis: DRAGON-06 trial.2022Future oncology (London, England)
  73. Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).2022Future oncology (London, England)
  74. A phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis.2022Future oncology (London, England)
  75. Atranorin driven by nano materials SPION lead to ferroptosis of gastric cancer stem cells by weakening the mRNA 5-hydroxymethylcytidine modification of the Xc-/GPX4 axis and its expression.2022International journal of medical sciences免费全文
  76. Application Value of 4K High-Definition System in Laparoscopic Gastrectomy: Preliminary Results and Initial Experience.2022Journal of laparoendoscopic & advanced surgical techniques. Part A
  77. Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA.2022Journal of translational medicine免费全文
  78. The dynamic alteration of transcriptional regulation by crucial TFs during tumorigenesis of gastric cancer.2022Molecular medicine (Cambridge, Mass.)免费全文
  79. Pangenomic analysis of Chinese gastric cancer.2022Nature communications免费全文
  80. A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer.2022Pathology oncology research : POR免费全文
  81. An xception model based on residual attention mechanism for the classification of benign and malignant gastric ulcers.2022Scientific reports免费全文
  82. Quantifying the cell morphology and predicting biological behavior of signet ring cell carcinoma using deep learning.2022Scientific reports免费全文
  83. Assessment of liver metastases radiomic feature reproducibility with deep-learning-based semi-automatic segmentation software.2021Acta radiologica (Stockholm, Sweden : 1987)
  84. Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases.2021BMC cancer免费全文
  85. A greater lymph node yield is required during pathological examination in microsatellite instability-high gastric cancer.2021BMC cancer免费全文
  86. LncRNA MALAT1 promotes gastric cancer progression via inhibiting autophagic flux and inducing fibroblast activation.2021Cell death & disease免费全文
  87. Identification of ARGLU1 as a potential therapeutic target for gastric cancer based on genome-wide functional screening data.2021EBioMedicine免费全文
  88. ATP5B promotes the metastasis and growth of gastric cancer by activating the FAK/AKT/MMP2 pathway.2021FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  89. A randomized controlled trial to evaluate omentum-preserving gastrectomy for patients with T1-T3 gastric cancer.2021Future oncology (London, England)
  90. YY1-modulated long non-coding RNA SNHG12 promotes gastric cancer metastasis by activating the miR-218-5p/YWHAZ axis.2021International journal of biological sciences免费全文
  91. Staged laparoscopic management of locally advanced gastric cancer with outlet obstruction.2021Journal of surgical oncology
  92. Impact of microsatellite status on negative lymph node count and prognostic relevance after curative gastrectomy.2021Journal of surgical oncology
  93. The Validity of the GLIM Criteria for Malnutrition in Hospitalized Patients with Gastric Cancer.2021Nutrition and cancer
  94. Comprehensive Analysis of Ferroptosis-Related Markers for the Clinical and Biological Value in Gastric Cancer.2021Oxidative medicine and cellular longevity免费全文
  95. Collective dynamics of gastric cancer cells in fluid.2021Physical review. E
  96. The cross-talk between tumor cells and activated fibroblasts mediated by lactate/BDNF/TrkB signaling promotes acquired resistance to anlotinib in human gastric cancer.2021Redox biology免费全文
中文论文(未计入)14
  1. [Current status and prospects of minimally invasive surgical treatment for gastric cancer].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Strategies for supra-pancreatic lymph node dissection in laparoscopic gastric cancer surgery].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Clinical application of intraperitoneal chemotherapy ports in patients with gastric cancer and peritoneal metastases].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Clinical value and implementation strategies of normothermic intraperitoneal and systemic chemotherapy (NIPS) in the treatment of gastric cancer with peritoneal metastasis].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Key measures to improve the efficacy of diagnosis and treatment of gastric cancer with peritoneal metastasis].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Analysis of discordant results between multiplex fluorescence PCR-capillary electrophoresis for microsatellite instability (MSI) detection and immunohistochemistry (IHC) for mismatch repair (MMR) protein expression in gastrointestinal aden2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
  7. [Clinical significance of combined therapy with immune checkpoint inhibitor in perioperative treatment for locally advanced gastric cancer or adenocarcinoma of gastroesophageal junction].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Clinical significance of immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer].2024Zhonghua yi xue za zhi
  9. [Preliminary analysis of the promotion effect of laparoscopic standardized surgical treatment for gastric cancer in regional medical centers in Shanghai].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  10. [Small steps to thousands of miles: a tribute to Chinese laparoscopic gastric cancer surgery].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  11. [Digestive tract reconstruction after laparoscopic proximal gastrectomy for adenocarcinoma of esophagogastric junction].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  12. [Strategies of chemotherapy for peritoneal metastasis of gastrointestinal cancer].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  13. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  14. [Current status and prospect of perioperative therapy for locally advanced gastric cancer].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)58
  1. GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis即将招募NCT07923396牵头方I期2026-11 启动
  2. LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study正在招募NCT07556640牵头方II期2026-04 启动
  3. Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging即将招募NCT07554742牵头方2026-04 启动
  4. Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer即将招募NCT06888037牵头方II期2025-03 启动
  5. Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer正在招募NCT07867392牵头方II期2025-02 启动
  6. Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer正在招募NCT07026149牵头方II期2025-06 启动
  7. IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer正在招募NCT07025889牵头方I/II期2025-06 启动
  8. Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer正在招募NCT07366528牵头方III期2025-12 启动
  9. Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis正在招募NCT06519591牵头方II期2025-02 启动
  10. Predicting Efficacy of Preoperative Immunotherapy in Advanced Gastric Cancer正在招募NCT07824479牵头方2025-06 启动
  11. The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.正在招募NCT06597526牵头方2024-06 启动
  12. Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer即将招募NCT04384601牵头方III期2021-09 启动
  13. Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer正在招募NCT05140746牵头方不分期2020-09 启动
  14. Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer进行中,不再招募NCT06693128牵头方II期2024-11 启动
  15. Effect of a Self-designed MET Exercise Intervention on Cancer-related Fatigue in Patients With Gastric Cancer已完成NCT05401045牵头方不分期2023-01 启动
  16. Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer状态不明NCT05171530牵头方I期2022-01 启动
  17. Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis状态不明NCT05002686牵头方II/III期2021-08 启动
  18. Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)状态不明NCT04932187牵头方I期2021-08 启动
  19. Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer状态不明NCT04781413牵头方I/II期2021-03 启动
  20. Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis状态不明NCT05204173牵头方II期2021-05 启动
  21. In-hospital Outcomes of Older Patients With Gastric Cancer and Their Risk Factors已完成NCT06185907牵头方2021-04 启动
  22. Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC)状态不明NCT04410887牵头方I/II期2020-12 启动
  23. Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)状态不明NCT04508686牵头方I期2020-08 启动
  24. ctDNA Screening in Advanced HER2 Positive Gastric Cancer状态不明NCT04520295牵头方2020-05 启动
  25. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer进行中,不再招募NCT04208347牵头方II/III期2019-12 启动
  26. Development and Validation of the Surgical Assessment and Healthcare (SAH) Index for Gastric Cancer Treatment Evaluation已完成NCT07180966牵头方2019-01 启动
  27. Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer已完成NCT03636893牵头方II期2018-08 启动
  28. mFLOT Chemotherapy as First-line Treatment in GC已完成NCT03606928牵头方I/II期2018-07 启动
  29. Feasibility and Safety of Neoadjuvant Chemotherapy (FLOT ) for Gastric Cancer Patients in China已完成NCT03646591牵头方2017-11 启动
  30. Escorting Octogenarian for Gastric Cancer Surgery已完成NCT03639792牵头方2016-01 启动
  31. Early Detection of Postoperative Anastomotic Leak by CT已完成NCT03632395牵头方(推断)2015-11 启动
  32. Prospective Assessment of Alignment Between Multimodal Artificial Intelligence and Multidisciplinary Team Decisions in Gastrointestinal Oncology即将招募NCT07746830研究中心2026-08 启动
  33. Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer:MetBio-GC正在招募NCT07076979研究中心2025-06 启动
  34. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer正在招募NCT06901531研究中心III期2025-05 启动
  35. Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer:MetBio-CRC正在招募NCT07068529研究中心2025-06 启动
  36. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China正在招募NCT06846996研究中心2025-02 启动
  37. Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study正在招募NCT06679244研究中心不分期2024-12 启动
  38. DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy正在招募NCT06221748研究中心II/III期2024-02 启动
  39. Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma正在招募NCT05918094研究中心III期2023-04 启动
  40. AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy正在招募NCT06035250研究中心2023-09 启动
  41. A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer正在招募NCT05365581研究中心I期2022-06 启动
  42. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  43. Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen状态不明NCT06036745研究中心II期2022-07 启动
  44. A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer已暂停NCT05101616研究中心I/II期2022-07 启动
  45. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  46. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  47. Performing Laparoscopic Surgery for Colorectal and Gastric Cancer Outside the Primary Registered Medical Institution已完成NCT04834661研究中心2021-10 启动
  48. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  49. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动
  50. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis状态不明NCT04440605研究中心2020-07 启动
  51. Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GC状态不明NCT04638959研究中心2019-09 启动
  52. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers状态不明NCT03468712研究中心不分期2018-03 启动
  53. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer已完成NCT03694522研究中心II期2018-09 启动
  54. Incidence of Pancreatic Fistula After Radical Gastrectomy状态不明NCT03391687研究中心2017-12 启动
  55. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)已终止NCT03019588研究中心III期2017-02 启动
  56. Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery状态不明NCT02130752研究中心不分期2014-10 启动
  57. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动
  58. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)状态不明NCT01609309研究中心III期2012-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 13 篇,占 0.6%。

牵头论文
13
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 5520222023: 2220232024: 0020242025: 222025

上海有 60 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial
    分期
    II期
    开始
    2023-06
    登记号
    NCT06114225

    年龄 10 岁 至 65 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室放疗科病理/检验科影像/核医学科普外/肝胆胰外科

这些论文过半是实验室或动物研究。

牵头的论文13
  1. Stereotactic Body Radiation Therapy Augmented Checkpoint Inhibitor Immunotherapy Response in Heavily Pretreated Metastatic Osteosarcoma.2026International journal of radiation oncology, biology, physics
  2. Chemotherapeutic drug-triggered AEP-cleaved G3BP1 orchestrates stress granules/nucleoli/mitochondria in osteosarcoma.2025Bone research
  3. Enhanced antitumor immunity of VNP20009-CCL2-CXCL9 via the cGAS/STING axis in osteosarcoma lung metastasis.2025Journal for immunotherapy of cancer
  4. Spectral computed tomography-guided radiotherapy of osteosarcoma utilizing BiOI nanosheets.2023Acta biomaterialia
  5. Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma.2023Journal of cancer research and clinical oncology
  6. Thrombospondin-1 induced programmed death-ligand 1-mediated immunosuppression by activating the STAT3 pathway in osteosarcoma.2022Cancer science
  7. Vessel state and immune infiltration of the angiogenesis subgroup and construction of a prediction model in osteosarcoma.2022Frontiers in immunology
  8. Superenhancers activate the autophagy-related genes Beclin1 and LC3B to drive metastasis and drug resistance in osteosarcoma.2022Frontiers of medicine
  9. DNA Base Pairing-Inspired Supramolecular Nanodrug Camouflaged by Cancer-Cell Membrane for Osteosarcoma Treatment.2022Small (Weinheim an der Bergstrasse, Germany)
  10. Current Status and Prospects of Clinical Treatment of Osteosarcoma.2022Technology in cancer research & treatment
  11. Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma.2021Cell death & disease
  12. Development and analysis of long non-coding RNA-associated competing endogenous RNA network for osteosarcoma metastasis.2021Hereditas
  13. Peritumoral Microgel Reservoir for Long-Term Light-Controlled Triple-Synergistic Treatment of Osteosarcoma with Single Ultra-Low Dose.2021Small (Weinheim an der Bergstrasse, Germany)
中文论文(未计入)1
  1. [Extraosseous Ewing's sarcoma of the pancreas: a clinicopathological analysis of 3 cases].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
早期论文(2016–2020 年)15
  1. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma.2020Aging
  2. Isolation of extracellular vesicle with different precipitation-based methods exerts a tremendous impact on the biomarker analysis for clinical plasma samples.2020Cancer biomarkers : section A of Disease markers
  3. Establishment of a dynamic osteosarcoma biobank: Ruijin experience.2020Cell and tissue banking
  4. Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma.2019Journal of immunotherapy (Hagerstown, Md. : 1997)
  5. Pre-Operative chemotherapy response assessed by contrast-enhanced MRI can predict the prognosis of Enneking surgical margins in patients with osteosarcoma.2019Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  6. ASO Author Reflections: Metastatic Biopsy of Osteosarcoma with Circulating RNA.2018Annals of surgical oncology
  7. Extracellular Vesicle RNA Sequencing Reveals Dramatic Transcriptomic Alterations Between Metastatic and Primary Osteosarcoma in a Liquid Biopsy Approach.2018Annals of surgical oncology
  8. Exosomal miR-675 from metastatic osteosarcoma promotes cell migration and invasion by targeting CALN1.2018Biochemical and biophysical research communications
  9. Adaptive Fibrogenic Reprogramming of Osteosarcoma Stem Cells Promotes Metastatic Growth.2018Cell reports
  10. Bone tumors developed in patients with juvenile inflammatory arthritis after anti-TNFα therapy.2018Immunotherapy
  11. Primary, cardiac, fibroblastic osteosarcoma: A case report.2018Medicine
  12. Patellar height influences knee function in patients with aggressive bone tumors of the proximal tibia after endoprosthetic reconstruction.2018The Knee
  13. Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo.2017Cancer science
  14. Rare Ileal Ewing Sarcoma/Primitive Neuroectodermal Tumor on 18F-FDG PET/CT.2017Clinical nuclear medicine
  15. Effects of resection margins on local recurrence of osteosarcoma in extremity and pelvis: Systematic review and meta-analysis.2016International journal of surgery (London, England)
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial正在招募NCT06114225牵头方II期2023-06 启动
  2. Construction of Microfluidic Exosome Chip for Diagnosis of Lung Metastasis of Osteosarcoma已完成NCT05101655牵头方2020-10 启动
  3. Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy状态不明NCT03742193牵头方II期2019-08 启动
  4. Circulating Exosome RNA in Lung Metastases of Primary High-Grade Osteosarcoma状态不明NCT03108677牵头方2017-05 启动
  5. A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma即将招募NCT05590572研究中心I/II期2023-01 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

上海有 21 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室肾内科消化/肝病科普外/肝胆胰外科
牵头的论文2
  1. A combined radiomic model distinguishing GISTs from leiomyomas and schwannomas in the stomach based on endoscopic ultrasonography images.2023Journal of applied clinical medical physics免费全文
  2. Clinical characteristics and outcomes of gastrointestinal stromal tumor patients receiving surgery with or without TKI therapy: a retrospective real-world study.2023World journal of surgical oncology
中文论文(未计入)1
  1. [Thrombotic microangiopathy caused by tyrosine kinase inhibitor in small intestine stromal tumor: a case report].2025Zhonghua nei ke za zhi
早期论文(2016–2020 年)5
  1. [Analysis and comparison of the clinical features and prognosis between extra - gastrointestinal stromal tumors and duodenal gastrointestinal stromal tumors].2019Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Analysis of clinical features and prognostic factors on reoperation patients with postoperative recurrence or metastasis of gastrointestinal stromal tumor].2018Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. Identifying therapeutic targets in gastric cancer: the current status and future direction.2016Acta biochimica et biophysica Sinica
  4. Facilitating retroflexed endoscopic full-thickness resection through loop-mediated or rope-mediated countertraction (with videos).2016Gastrointestinal endoscopy
  5. Comparison of the post-operative outcomes and survival of laparoscopic versus open resections for gastric gastrointestinal stromal tumors: A multi-center prospective cohort study.2016International journal of surgery (London, England)

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

上海有 34 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 15 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科
中文论文(未计入)1
  1. [Extraosseous Ewing's sarcoma of the pancreas: a clinicopathological analysis of 3 cases].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
早期论文(2016–2020 年)1
  1. Rare Ileal Ewing Sarcoma/Primitive Neuroectodermal Tumor on 18F-FDG PET/CT.2017Clinical nuclear medicine

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 22 篇,占 1.3%。

牵头论文
22
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 3320232024: 6620242025: 10102025

上海有 16 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
    分期
    I期
    开始
    2026-09
    登记号
    NCT07914556

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

  2. 正在招募
    A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
    分期
    早期I期
    开始
    2025-12
    登记号
    NCT07294625

    年龄 18 岁 至 未注明(登记的条件)

    牵头:江苏省人民医院(南医大一附院);另有 4 家列出的医院为研究中心上海、南京、徐州、西安、郑州

  3. 正在招募
    A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
    分期
    I期
    开始
    2023-03
    登记号
    NCT05759793

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

  4. 正在招募
    A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
    分期
    IV期
    开始
    2022-03
    登记号
    NCT05201781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南京、广州、成都、杭州、福州、西安

  5. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题CAR-T 与细胞治疗诊断、微小残留病与危险分层复发与耐药
论文中的科室影像/核医学科
牵头的论文22
  1. Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma.2026Chinese medical journal免费全文
  2. Targeting the HuR/E2F7 axis synergizes with bortezomib against multiple myeloma.2025Acta pharmacologica Sinica免费全文
  3. Therapy related acute myeloid leukemia secondary to CAR-T therapy in refractory/relapsed multiple myeloma patient showing poor prognosis.2025Annals of hematology免费全文
  4. Exploring secondary extramedullary myeloma disease: a five-predictor scoring system with spotlight on double-hit cytogenetics.2025BMC medicine免费全文
  5. Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma.2025Blood advances免费全文
  6. Interleukin-5 is an adjunctive biomarker for engraftment syndrome in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation.2025Clinical immunology (Orlando, Fla.)
  7. Challenges facing CAR T-cell immunotherapy in multiple myeloma.2025Critical reviews in oncology/hematology
  8. Prognostic value of [18F]fluorodeoxyglucose-PET/MRI(CT) novel interpretation criteria (IMPeTUs) in multiple myeloma.2025European journal of nuclear medicine and molecular imaging
  9. Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma.2025Frontiers in immunology免费全文
  10. Myeloma cell-intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy.2025Molecular therapy : the journal of the American Society of Gene Therapy免费全文
  11. Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma.2025Scientific reportsRCT免费全文
  12. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.2024BMC cancer免费全文
  13. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion.2024Journal for immunotherapy of cancer免费全文
  14. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.2024Journal of hematology & oncology免费全文
  15. Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma.2024Nature communications免费全文
  16. Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A.2024PloS one免费全文
  17. Integrative analysis of an endoplasmic reticulum stress-related signature in multiple myeloma.2024The journal of gene medicine
  18. Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma.2023European journal of cancer (Oxford, England : 1990)
  19. Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).2023Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  20. Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity.2023Signal transduction and targeted therapy免费全文
  21. SPAG5 as a novel biomarker and potential therapeutic target via regulating AKT pathway in multiple myeloma.2022Leukemia & lymphoma
  22. Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance.2021British journal of cancer免费全文
中文论文(未计入)7
  1. [Characteristics and Risk Analysis of COVID-19 Infection in Patients with Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation].2025Zhongguo shi yan xue ye xue za zhi
  2. [Effect of different induction chemotherapy regimens on autologous hematopoietic stem cell mobilization in patients with multiple myeloma in the new drug era].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  3. [Research progress on targeted delivery of proteasome inhibitor nanoparticles for the treatment of multiple myeloma].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  4. [Research progress in targeting GPRC5D for the treatment of multiple myeloma].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  5. [Effects of extramedullary disease on patients with newly diagnosed multiple myeloma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  6. [Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  7. [Clinical characteristics and prognosis of patients with newly-diagnosed multiple myeloma with t(11;14)].2022Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)23
  1. Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients已终止NCT00984828牵头方(推断)II/III期2009-08 启动
  2. Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma已暂停NCT00892346牵头方(推断)III期2009-05 启动
  3. Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers正在招募NCT07914556研究中心I期2026-09 启动
  4. A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma正在招募NCT07294625研究中心早期I期2025-12 启动
  5. A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia正在招募NCT05759793研究中心I期2023-03 启动
  6. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel正在招募NCT05201781研究中心IV期2022-03 启动
  7. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  8. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide进行中,不再招募NCT06208150研究中心III期2024-01 启动
  9. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)进行中,不再招募NCT06464991研究中心III期2024-03 启动
  10. A Study of Daratumumab进行中,不再招募NCT05438043研究中心III期2022-12 启动
  11. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)已完成NCT04939142研究中心III期2021-07 启动
  12. A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma已终止NCT04735575研究中心I/II期2021-05 启动
  13. A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma状态不明NCT05271682研究中心I期2021-12 启动
  14. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)状态不明NCT05066646研究中心I/II期2020-04 启动
  15. A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已终止NCT03758417研究中心II期2019-01 启动
  16. Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)已完成NCT03748953研究中心III期2019-01 启动
  17. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动
  18. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.进行中,不再招募NCT03539744研究中心III期2018-10 启动
  19. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  20. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已完成NCT03234972研究中心III期2017-11 启动
  21. A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)已完成NCT02312258研究中心III期2015-04 启动
  22. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma已完成NCT01818752研究中心III期2013-07 启动
  23. Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma已完成NCT00689936研究中心III期2008-08 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 11 篇,占 4.9%。

牵头论文
11
2021–2025 年
牵头试验
6
任何状态,ClinicalTrials.gov
牵头的开放试验
4
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 0020222023: 2220232024: 3320242025: 332025

上海有 9 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
    分期
    I期
    开始
    2026-05
    登记号
    NCT07838714

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  2. 正在招募
    Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
    分期
    II期
    开始
    2024-12
    登记号
    NCT06718244

    年龄 16 岁 至 70 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  3. 即将招募
    Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia
    分期
    不分期
    开始
    2025-09
    登记号
    NCT07087847

    年龄 18 岁 至 未注明(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  4. 即将招募
    BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
    分期
    II期
    开始
    2025-12
    登记号
    NCT07301138

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  5. 即将招募
    Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL
    分期
    I期
    开始
    2024-11
    登记号
    NCT06641024

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题费城染色体与遗传学抗体与靶向药物干细胞移植
牵头的论文11
  1. Resolving Leukemia Heterogeneity and Lineage Aberrations with HematoMap.2025Genomics, proteomics & bioinformatics免费全文
  2. Differences in response to immunotherapy drugs including blinatumomab and inotuzumab ozogamicin in B-ALL patients.2025International journal of hematology
  3. Targeting HDAC8 sensitizes tyrosine kinase inhibitors in the elimination of B-cell acute lymphoblastic leukemia cells through degradation of HIF-1α.2025Leukemia
  4. BCR::ABL1-Like B-Cell Acute Lymphoblastic Leukemia with BCR::PDGFRA Fusion: A Case Report and Literature Review.2024Acta haematologica
  5. Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia/lymphoma following allogeneic hematopoietic cell transplantation.2024Blood cancer journal免费全文
  6. Integrative alternative splicing analysis reveals new prognosis signature in B-cell acute lymphoblastic leukemia.2024International journal of biological sciences免费全文
  7. Transcription factor 12-mediated self-feedback regulatory mechanism is required in DUX4 fusion leukaemia.2023Clinical and translational medicine免费全文
  8. Transcription factor abnormalities in B-ALL leukemogenesis and treatment.2023Trends in cancer
  9. Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation.2021Frontiers in immunology免费全文
  10. Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.2021Frontiers of medicine
  11. Purification, crystallization, and X-ray diffraction analysis of myocyte enhancer factor 2D and DNA complex.2021Protein expression and purification
中文论文(未计入)1
  1. [Clinical analysis of 16 cases of adult acute B-lymphoblastic leukemia treated with blinatumomab].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia正在招募NCT07838714牵头方I期2026-05 启动
  2. BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients即将招募NCT07301138牵头方II期2025-12 启动
  3. Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia即将招募NCT07087847牵头方不分期2025-09 启动
  4. Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1正在招募NCT06718244牵头方II期2024-12 启动
  5. A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19进行中,不再招募NCT07269587牵头方2025-11 启动
  6. A Multi-center Retrospective Study of INO Treating B-ALL进行中,不再招募NCT07238907牵头方2022-06 启动
  7. Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL即将招募NCT06641024研究中心I期2024-11 启动
  8. To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.状态不明NCT05223686研究中心I期2022-02 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

上海有 5 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录
研究主题治疗方案EB病毒与感染诱因淋巴瘤及肿瘤相关噬血
论文中的科室风湿免疫科
牵头的论文2
  1. Ruxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome.2025Blood免费全文
  2. Risk factors for secondary hemophagocytic lymphohistiocytosis in severe coronavirus disease 2019 adult patients.2021BMC infectious diseases免费全文
中文论文(未计入)1
  1. [Clinical features and risk factors for secondary hemophagocytic lymphohistiocytosis in elderly patients with severe SARS-CoV-2 infection: a multicenter retrospective cohort study].2023Zhonghua wei zhong bing ji jiu yi xue
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))已完成NCT07034209研究中心II期2023-04 启动
PubMed 以外找到的论文(未计入)5
  1. POS0387 NEUTROPHIL EXTRACELLULAR TRAPS ACCELERATE CYTOKINE STORM IN AUTOIMMUNE AND AUTOINFLAMMATORY DISEASE BY PROMOTING STING-MEDIATED MYELOPOIEIS2025Annals of the Rheumatic Diseases会议摘要
  2. POS1430 GENETIC LANDSCAPE OF ADULT-ONSET STILL'S DISEASE WITH MACROPHAGE ACTIVATION SYNDROME: IDENTIFYING KEY RISK LOCI FOR DISEASE MECHANISMS AND PERSONALIZED TREATMENT2025Annals of the Rheumatic Diseases会议摘要
  3. Ruxolitinib concentrations in cerebrospinal fluid in patients with hemophagocytic lymphohistiocytosis and potential significance of central nervous system involvement2025Blood会议摘要
  4. The prospect of high-dose vitamin c in improving early survival in patients with hemophagocytic lymphohistiocytosis2025Blood会议摘要
  5. Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up2022Blood论文

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年没有牵头β 地中海贫血的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头

上海有 7 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    β-Thalassemia Treatment With KL003 Cell Injection
    分期
    I/II期
    开始
    2024-04
    登记号
    NCT06280378

    年龄 3 岁 至 35 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、天津

  2. 正在招募
    A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
    分期
    I期
    开始
    2024-01
    登记号
    NCT06465550

    年龄 3 岁 至 35 岁(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、南宁、广州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科
中文论文(未计入)1
  1. [Study of the types of mutations of Thalassemia in Shanghai area].2024Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major正在招募NCT06465550研究中心I期2024-01 启动
  2. β-Thalassemia Treatment With KL003 Cell Injection正在招募NCT06280378研究中心I/II期2024-04 启动
  3. A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major即将招募NCT07489196研究中心II期2026-04 启动
  4. A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major已完成NCT06291961研究中心I期2024-04 启动
  5. Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia状态不明NCT05776173研究中心不分期2023-08 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 5 篇,占 1.8%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 1120232024: 0020242025: 112025

上海有 9 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录
论文中的科室病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文5
  1. Single-cell sequencing on PBMCs from patients with HA and HB with inhibitors reveals different immune responses to FVIII and FIX.2025Blood advances
  2. Tandem and inverted duplications in haemophilia A: Breakpoint characterisation provides insight into possible rearrangement mechanisms.2023Haemophilia : the official journal of the World Federation of Hemophilia
  3. Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain.2022Frontiers of medicine
  4. Characteristics of the Thrombus Formation in Transgenic Mice with Platelet-Targeted Factor VIII Expression.2022Thrombosis and haemostasis
  5. Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B.2021Clinical and translational medicine
中文论文(未计入)1
  1. [Perioperative management of a patient with hemophilia a and high-titer inhibitors and literature review].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
早期论文(2016–2020 年)11
  1. Maternal microchimerism protects hemophilia A patients from inhibitor development.2020Blood advances
  2. In vivo generated hematopoietic stem cells from genome edited induced pluripotent stem cells are functional in platelet-targeted gene therapy of murine hemophilia A.2020Haematologica
  3. [A case of acquired hemophilia A with multiple superficial blistering skin disorders as the main manifestation].2020Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  4. [Optimized AAV package and experimental application of recombinant AAV8/hFⅧ for gene therapy on hemophilia A mice].2020Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  5. Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII.2019Blood
  6. Inhibitor eradication and bleeding management of acquired hemophilia A: a single center experience in China.2019Hematology (Amsterdam, Netherlands)
  7. Evaluation of the activity levels of rat FVIII and human FVIII delivered by adeno-associated viral vectors both in vitro and in vivo.2018Blood cells, molecules & diseases
  8. Spectrum and origin of mutations in sporadic cases of haemophilia A in China.2018Haemophilia : the official journal of the World Federation of Hemophilia
  9. Complex recombination with deletion in the F8 and duplication in the TMLHE mediated by int22h copies during early embryogenesis.2017Thrombosis and haemostasis
  10. AccuCopy quantification combined with pre-amplification of long-distance PCR for fast analysis of intron 22 inversion in haemophilia A.2016Clinica chimica acta; international journal of clinical chemistry
  11. Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment.2016Gene therapy
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products已完成NCT06738485研究中心III期2025-01 启动
  2. Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor已完成NCT06289166研究中心II期2024-03 启动
  3. An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency正在招募NCT07644832研究中心I/II期2024-05 启动
  4. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein已完成NCT06142552研究中心III期2023-12 启动
  5. Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants已完成NCT03315455研究中心III期2018-04 启动
  6. Evaluate Efficacy and Safety of Recombinant Factor VIII (rFVIII)Treatment of Severe or Moderately Severe Hemophilia A状态不明NCT02930317研究中心III期2016-08 启动
  7. PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A已完成NCT02492984研究中心IV期2015-04 启动
  8. China ADVATE PTP Study已完成NCT02170402研究中心IV期2014-06 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年没有牵头血栓性血小板减少性紫癜的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 2 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)状态不明NCT04021173研究中心II期2019-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.6%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

上海有 4 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。

这些数字背后的记录
研究主题影像与脑血流血管重建手术中风与出血
论文中的科室神经外科神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

上海有 9 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年没有牵头特发性肺纤维化的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 34 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肺淋巴管平滑肌瘤病

Lymphangioleiomyomatosis

2021–2025 年中国大陆作者发表的 45 篇肺淋巴管平滑肌瘤病 PubMed 英文论文中,这家医院牵头了 2 篇,占 4.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

上海有 2 家医院列在肺淋巴管平滑肌瘤病下全国有 28 家医院列在肺淋巴管平滑肌瘤病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肺淋巴管平滑肌瘤病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

上海有 17 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊髓性肌萎缩症

Spinal muscular atrophy

2021–2025 年没有牵头脊髓性肌萎缩症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 6 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊髓性肌萎缩症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 3 篇,占 4.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

上海有 6 家医院列在法布雷病下全国有 85 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录
论文中的科室肾内科眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年中国大陆作者发表的 58 篇Alport 综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

上海有 5 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录
论文中的科室肾内科
牵头的论文1
  1. Tauroursodeoxycholic acid ameliorates renal injury induced by COL4A3 mutation.2024Kidney international
早期论文(2016–2020 年)1
  1. [Advances in research on gene and cell therapy for type IV collagen related hereditary kidney diseases].2019Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.5%。

牵头论文
4
2021–2025 年
牵头试验
7
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

上海有 26 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of Telitacicept in IgAN
    分期
    不分期
    开始
    2024-12
    登记号
    NCT06654596

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  2. 正在招募
    The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
    分期
    未注明
    开始
    2020-12
    登记号
    NCT04858724

    年龄未注明(登记的条件)

    牵头:上海交通大学医学院附属瑞金医院上海

  3. 正在招募
    A Study of SHR-2173 in Participants With Primary IgA Nephropathy
    分期
    II期
    开始
    2026-03
    登记号
    NCT07354932

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、广州

  4. 正在招募
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    分期
    III期
    开始
    2025-07
    登记号
    NCT06963827

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、包头、北京、南京、南昌、南通、厦门、宁波、广州、成都、无锡、杭州、济南、深圳、珠海、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肾内科
牵头的论文4
  1. Thickening of Glomerular Basement Membrane Is Associated with Long-Term Prognosis in Patients with IgA Nephropathy.2026Kidney360
  2. Uncovering Rare Coding Variants in IgA Nephropathy.2023Journal of the American Society of Nephrology : JASN
  3. Particulate matter of air pollution may increase risk of kidney failure in IgA nephropathy.2022Kidney international
  4. A Validation Study Comparing Risk Prediction Models of IgA Nephropathy.2021Frontiers in immunology
早期论文(2016–2020 年)9
  1. A Rare Genetic Defect of MBL2 Increased the Risk for Progression of IgA Nephropathy.2019Frontiers in immunologyRCT
  2. Kidney Failure Risk Prediction Equations in IgA Nephropathy: A Multicenter Risk Assessment Study in Chinese Patients.2018American journal of kidney diseases : the official journal of the National Kidney Foundation
  3. IgA Nephropathy Susceptibility Loci and Disease Progression.2018Clinical journal of the American Society of Nephrology : CJASN
  4. A validation study of crescents in predicting ESRD in patients with IgA nephropathy.2018Journal of translational medicine
  5. [The clinicopathological characteristics of diabetic nephropathy and non-diabetic renal diseases in diabetic patients].2017Zhonghua nei ke za zhi
  6. Histone deacetylase inhibitors attenuate P-aIgA1-induced cell proliferation and extracellular matrix synthesis in human renal mesangial cells in vitro.2016Acta pharmacologica Sinica
  7. Fine Mapping Implicates a Deletion of CFHR1 and CFHR3 in Protection from IgA Nephropathy in Han Chinese.2016Journal of the American Society of Nephrology : JASN
  8. Bilateral Posterior Scleritis Presenting as the First Manifestation of Immunoglobulin A Nephropathy: Case Report and Review of the Literature.2016Ocular immunology and inflammation
  9. Underweight Is an Independent Risk Factor for Renal Function Deterioration in Patients with IgA Nephropathy.2016PloS one
它在 ClinicalTrials.gov 上的全部试验(任何状态)13
  1. Efficacy and Safety of Telitacicept in IgAN正在招募NCT06654596牵头方不分期2024-12 启动
  2. The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)正在招募NCT04858724牵头方2020-12 启动
  3. Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions即将招募NCT07888335牵头方IV期2026-12 启动
  4. Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN已完成NCT06589752牵头方2023-04 启动
  5. Bortezomib for Treating Glomerular Diseases状态不明NCT05383547牵头方不分期2022-08 启动
  6. Rituximab and RASi in Patients with IgAN已完成NCT04525729牵头方(推断)IV期2020-07 启动
  7. A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy状态不明NCT05824390牵头方(推断)IV期2020-06 启动
  8. A Study of SHR-2173 in Participants With Primary IgA Nephropathy正在招募NCT07354932研究中心II期2026-03 启动
  9. A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy正在招募NCT06963827研究中心III期2025-07 启动
  10. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases即将招募NCT06774664研究中心I/II期2025-01 启动
  11. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression进行中,不再招募NCT05797610研究中心III期2023-08 启动
  12. TESTING -ON Post-Trial ObservatioNal Cohort Study已完成NCT05434325研究中心2022-12 启动
  13. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)已完成NCT01560052研究中心不分期2012-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

上海有 17 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    分期
    III期
    开始
    2025-12
    登记号
    NCT07282353

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心Baoji、上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA正在招募NCT07282353研究中心III期2025-12 启动
  2. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis已完成NCT01857284研究中心III期2009-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

上海有 9 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

上海交通大学医学院附属瑞金医院

Ruijin Hospital

上海

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Rui-Jin Hospital; Rui Jin Hospital; Ruijin Hospital North; Wuxi Branch of Ruijin Hospital; Rui Jin Hospital affiliated with Shanghai Jiaotong University; Ruijin Hospital/Lu Wan Branch; RuiJin Hospital; Medical Center on Aging of Ruijin Hospital

提出更正下载数据